Johann S. de Bono

Research interests

Publications

• Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2107322

• Pan-cancer analysis of whole genomes

  Nature · 2020 · https://doi.org/10.1038/s41586-020-1969-6

• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2022485

• Olaparib for Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1911440

• Genomic correlates of clinical outcome in advanced prostate cancer

  Proceedings of the National Academy of Sciences · 2019 · https://doi.org/10.1073/pnas.1902651116

• Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

  Science · 2018 · https://doi.org/10.1126/science.aao2774

• The long tail of oncogenic drivers in prostate cancer

  Nature Genetics · 2018 · 10.1038/s41588-018-0078-z

• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1702900

• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.2702

• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1603144

• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(14)71205-7

• Integrative Clinical Genomics of Advanced Prostate Cancer

  Cell · 2015 · https://doi.org/10.1016/j.cell.2015.05.001

• Prostate cancer

  The Lancet · 2015 · 10.1016/s0140-6736(14)61947-4

• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1506859

• Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)01037-5

• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1405095

• Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1207506

• Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1209096

• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70379-0

• Abiraterone and Increased Survival in Metastatic Prostate Cancer

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1014618

• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

  The Lancet · 2010 · 10.1016/s0140-6736(10)61389-x

• Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.26.9589

• Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0900212

• Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.9749

• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-08-0872

Current projects

No projects listed.